Aura Biosciences Gelecekteki Büyüme

Future kriter kontrolleri 0/6

Aura Biosciences şirketinin kazançlarının yıllık 8.9% oranında düşmesi, yıllık gelirinin ise yıllık 78.3% oranında artması bekleniyor. EPS'nin yıllık 5.5% oranında düşüşmesi bekleniyor.

Anahtar bilgiler

-8.9%

Kazanç büyüme oranı

-5.5%

EPS büyüme oranı

Biotechs kazanç büyümesi	28.4%
Gelir büyüme oranı	78.3%
Gelecekteki özkaynak getirisi	n/a
Analist kapsamı	Good
Son güncelleme	14 Nov 2024

Gelecekteki son büyüme güncellemeleri

Güncelleme yok

Recent updates

Companies Like Aura Biosciences (NASDAQ:AURA) Are In A Position To Invest In Growth

Mar 28

We Think Aura Biosciences (NASDAQ:AURA) Can Afford To Drive Business Growth

Oct 01

Aura gains as JMP starts with Bullish view citing treatment platform

Jul 19

Aura Biosciences' AU-011 gets FDA fast-track status for bladder cancer

Jun 30

Companies Like Aura Biosciences (NASDAQ:AURA) Are In A Position To Invest In Growth

Apr 10

Kazanç ve Gelir Büyüme Tahminleri

NasdaqGM:AURA - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (USD Millions )
Tarih	Gelir	Kazançlar	Serbest Nakit Akışı	Faaliyetlerden Nakit	Avg. Analist Sayısı
12/31/2026	N/A	-120	-156	-106	5
12/31/2025	N/A	-100	-109	-85	7
12/31/2024	N/A	-83	-81	-77	7
9/30/2024	N/A	-83	-75	-73	N/A
6/30/2024	N/A	-81	-74	-73	N/A
3/31/2024	N/A	-79	-73	-72	N/A
12/31/2023	N/A	-76	-65	-64	N/A
9/30/2023	N/A	-71	-65	-64	N/A
6/30/2023	N/A	-68	-61	-60	N/A
3/31/2023	N/A	-63	-56	-56	N/A
12/31/2022	N/A	-59	-56	-55	N/A
9/30/2022	N/A	-55	-50	-49	N/A
6/30/2022	N/A	-52	-49	-47	N/A
3/31/2022	N/A	-51	-45	-42	N/A
12/31/2021	N/A	-46	-35	-32	N/A
9/30/2021	N/A	-40	-26	-24	N/A
6/30/2021	N/A	-33	-23	-22	N/A
3/31/2021	N/A	-29	-22	-21	N/A
12/31/2020	N/A	-30	-25	-24	N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: AURA önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Kazançlar ve Piyasa: AURA önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Yüksek Büyüme Kazançları: AURA önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Gelir ve Pazar: AURA gelecek yıl gelir elde edemeyeceği tahmin ediliyor.

Yüksek Büyüme Geliri: AURA gelecek yıl gelir elde edemeyeceği tahmin ediliyor.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: AURA 'un Özsermaye Getirisi'nin 3 yıl içinde yüksek olmasının öngörülüp öngörülmediğini belirlemek için yeterli veri yok

Aura Biosciences Gelecekteki Büyüme

Future kriter kontrolleri 0/6

Anahtar bilgiler

Gelecekteki son büyüme güncellemeleri

Recent updates

Aura Biosciences, Inc. Announces Positive Early Data from an Ongoing Phase 1 Clinical Trial of Bel-sar (AU-011) in Patients with NMIBC

Aura Biosciences: Highly Derisked Late-Stage Eye Cancer Company

Aura Biosciences, Inc. Reports Positive Phase 2 End of Study Results Evaluating Bel-Sar as A First- Line Treatment for Early-Stage Choroidal Melanoma

We're Hopeful That Aura Biosciences (NASDAQ:AURA) Will Use Its Cash Wisely

Aura Biosciences, Inc., Annual General Meeting, Jun 20, 2024

Aura Biosciences, Inc., Annual General Meeting, Jun 20, 2024

New minor risk - Insider selling

Founder recently sold US$121k worth of stock

Aura Biosciences Announces First Patient Dosed in Global Phase 3 CoMpass Trial Evaluating the Safety and Efficacy of Belzupacap Sarotalocan (Bel-Sar) for First-Line Treatment of Early-Stage Choroidal Melanoma

Independent Chairman of the Board recently bought US$1.4m worth of stock

Founder notifies of intention to sell stock

Aura Biosciences, Inc. has filed a Follow-on Equity Offering in the amount of $99 million.

Aura Biosciences, Inc. has filed a Follow-on Equity Offering.

New minor risk - Share price stability

Founder recently sold US$65k worth of stock

Aura Biosciences to Present Updated Phase 2 Data Evaluating Suprachoroidal Administration of Belzupacap Sarotalocan (Bel-sar) for the First-Line Treatment of Patients with Early-Stage Choroidal Melanoma at AAO 2023

Independent Chairman of the Board recently bought US$168k worth of stock

Aura Biosciences, Inc. Announces Executive Changes

We Think Aura Biosciences (NASDAQ:AURA) Can Afford To Drive Business Growth

Companies Like Aura Biosciences (NASDAQ:AURA) Are In A Position To Invest In Growth

Aura Biosciences, Inc. Announces Positive Interim Phase 2 Safety and Efficacy Data of Belzupacap Sarotalocan for the First-Line Treatment of Patients with Early-Stage Choroidal Melanoma with Suprachoroidal Administration At the Macula Society 46Th Annual Meeting

Aura Announces Inc. Global Phase 3 Trial Design with Suprachoroidal Route of Administration Based on Positive Phase 2 Interim Data of Belzupacap Sarotalocan in Early-Stage Choroidal Melanoma

Aura Biosciences Announces Interim Phase 2 Data Evaluating Suprachoroidal Administration of Belzupacap Sarotalocan (Au-011) for the First-Line Treatment of Patients with Early-Stage Choroidal Melanoma Presented At Aao 2022

We Think Aura Biosciences (NASDAQ:AURA) Can Afford To Drive Business Growth

Aura Biosciences Announces First Patient Dosed in Phase 1 Study Evaluating Belzupacap Sarotalocan (AU-011) for the Treatment of Non-Muscle Invasive Bladder Cancer

Aura Biosciences Inc. to Present Belzupacap Sarotalocan (AU-011) Data from Multiple Studies at the 22nd EURETINA Congress

Aura gains as JMP starts with Bullish view citing treatment platform

Aura Biosciences Receives Fda Fast Track Designation for Belzupacap Sarotalocan (Au-011) for the Treatment of Non-Muscle Invasive Bladder Cancer

Aura Biosciences' AU-011 gets FDA fast-track status for bladder cancer

Aura Biosciences, Inc.(NasdaqGM:AURA) dropped from Russell 2500 Value Index

Aura Biosciences Reports Topline Data from a Retrospective Study of Belzupacap Sarotalocan (AUu-011) Versus Plaque Radiotherapy Supporting the Value of a Vision Preserving Therapy for the Treatment of Patients with Early-Stage Choroidal Melanoma

Aura Biosciences Present Updates Belzupacap Sarotalocan (Au-011) Data on Multiple Studies At the International Society of Ocular Oncology 2022 Bi-Annual Meeting

Independent Chairman of the Board recently bought US$716k worth of stock

Aura Biosciences, Inc. Announces Publication of Preclinical Data of the Combination of VDCs with Immune Checkpoint Inhibitors at the 2022 ASCO Annual Meeting

Aura Biosciences, Inc. Presents Preclinical Data Highlighting AU-011’s Anti-Tumor Activity in Choroidal Metastasis, an Additional Ocular Oncology Indication at the 2022 ARVO Annual Meeting

Companies Like Aura Biosciences (NASDAQ:AURA) Are In A Position To Invest In Growth

Aura Biosciences, Inc. to Present Preclinical Data Demonstrating Applicability of AU-011 in Bladder Cancer at the 2022 ASCO Genitourinary Cancer Symposium

Kazanç ve Gelir Büyüme Tahminleri

Analist Gelecek Büyüme Tahminleri

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Büyüyen şirketleri keşfedin